Ms. Sarno has approximately 25 years of life sciences’ industry experience, in roles in business development, strategic alliance, program management, and research at companies including Pfenex Inc. (acquired by Ligand Pharmaceuticals), Latham Biopharm Group, and Crucell (acquired by J&J). Most recently she served as the Vice President of Business Development and Corporate Strategy at Homology Medicines, where she led partnering …
Director, Machine Learning Research & Development Alex drives the development of iBio’s machine learning branch for epitope-steered antibody discovery. He has built his career around integrating machine learning into biotechnology platforms to solve problems in healthcare. With more than a decade of experience as a Ph.D. in computational biology, Alex has over 30 publications to …
Associate Director, Platform Development Cody develops iBio’s systems for in-vitro display, automation, and multi-specific antibody development. He is passionate about designing integrated laboratory and computational systems to solve complex biological problems. Before iBio, Cody was the first scientist at RubrYc Therapeutics, where he was responsible for establishing in-vitro display and sequencing capabilities while connecting them …
Mr. Clark has more than 30 years of biopharmaceutical experience. He is currently the Co-founder and CEO of Vibrant Biomedicines, a venture-backed developer of vaccines targeted bacterial pathogens. Prior to joining Vibrant Biomedicines, Mr. Clark served as Chief Executive Officer of Nasdaq-listed biopharmaceutical company, Genocea Biosciences, Inc.. Prior to joining Genocea, Mr. Clark was Chief …
Dr. Kropotova is a biopharmaceutical executive with 20+ years of global R&D experience in all phases of global clinical development, translational medicine, and medical affairs. Currently, she is Executive Vice President & Chief Medical Officer at SAb Biotherapeutics, leading the strategy, direction, and execution of the company’s portfolio of innovative polyclonal antibody assets. Prior to …